Are PD-1T TILs merely an expensive and unuseful whim as biomarker?
Esther Garcia-Lorenzo,Victor Moreno
DOI: https://doi.org/10.21037/tlcr-24-255
2024-09-02
Translational Lung Cancer Research
Abstract:Esther Garcia-Lorenzo, Victor Moreno START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain Comment on: Hummelink K, Tissier R, Bosch LJW, et al . A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics. Clin Cancer Res 2024;30:814-23. Keywords: Programmed cell death-ligand 1 (PD-L1); biomarker; immunotherapy; non-small cell lung cancer (NSCLC) Submitted Mar 18, 2024. Accepted for publication Jul 03, 2024. Published online Aug 23, 2024. doi: 10.21037/tlcr-24-255 Non-small cell lung cancer (NSCLC) represents the second most prevalent cancer in the world and the leading cause of mortality (1). The advent of drugs targeting Programmed cell death 1 (PD-1), such as pembrolizumab and nivolumab, and programmed cell death-ligand 1 (PD-L1), like atezolizumab, has significantly improved outcomes (2-5). These drugs have demonstrated efficacy in NSCLC through various clinical trials, showing superiority over the previously stablished standard platinum-based treatment (6,7). Despite these advancements, not all patients benefit from immunotherapy (8,9). The current standard for predicting response is assessing PD-L1 expression using immunochemistry (IHC). Nonetheless, the predictive accuracy of PD-L1 is compromised by technical variables such as the choice of detection antibody and cutoff values, as well as biological factors, including the widespread expression of PD-L1 on cell membranes due to oncogene activation and the variability within the tumor microenvironment (8). Considering all the uncertainties about PD-L1 determination and its value as a predictor of response, recent studies have shown a myriad of promising alternative biomarkers. These include PD-L1 T-cell immunohistochemistry (assessing PD-L1 expression on tumor-infiltrating T cells), the co-expression of additional immunological markers [such as PD-L2 and fractalkine (CX3CL1), T-cell immunoglobulin-3 (Tim-3), lymphocyte-activation gene (LAG-3) and co-stimulatory molecules like OX40 and 41BB] and T-cell receptor (TCR) clonality (indicating a more clonal T-cell population surrounding or infiltrating the tumor) (8). In this context, there has been considerable effort to identify new markers capable of distinguishing patients who are less likely derive benefit from immunotherapy. Hummelink et al. have identified a specific subpopulation of CD8 + tumor-infiltrating lymphocyte (TIL), named PD-1T TILs, whose presence was associated with higher response and longer survival in patients with NSCLC treated with anti-PD-1 therapy (10). PD-1T TILs are a subset of PD-1 + T cells that are characterized by their high expression of PD-1 (>90 PD-1T TILs/mm 2 ) and are transcriptionally and functionally distinct from other TIL populations with low or no expression of PD-1 (<90 PD-1T TILs/mm 2 ) (10). These PD-1T TILs show high tumor reactivity and are predominantly located in tertiary lymphoid structures (TLS), recognized as predictors of response to immune-checkpoint inhibitors in various tumor types, such as melanoma (10). Consequently, the absence of PD-1T TILs suggest a deficiency in tumor-reactive T-cell populations, thereby facilitating the identification of patients less likely to respond to immunotherapy (10). Hummelink et al. described a methodology for quantifying PD-1T TILs via IHC aimed at reducing human error stemming from manual processes throughout the procedure. Despite these advancements, the technique still necessitates significant user involvement, which could hinder its practical application in routine clinical settings due to interobserver variability that undermines the test's predictive accuracy. However, it merits acknowledgement that, according to the investigators, this novel biomarker yielded a sensitivity of 77% and a specificity of 67% to detect patients in response after 6 months of treatment with pembrolizumab or nivolumab. These results improved to 93% and 65% respectively for identifying those in response after 12 months, with a negative predictive value (NPV) of 88% at 6 months and 98% at 12 months. Additionally, a high presence of PD-1T TILs was associated with significantly longer progression-free survival (PFS) and overall survival (OS). Notably, the predictive performance of PD-1T TILs was superior to that of PD-L1 and TLS in the same cohort (10). In an effort to standardize this biomarker, the research team now introduces an updated version of their proposed biomarker. In this new article, they aim to stablish a robust RNA signature capable of determining a tumor's PD-1T TILs status using NanoString nCounter platform technology (9). The nCounter technology provides a robust method for multiplexing up to 800 gene expression target -Abstract Truncated-
oncology,respiratory system